Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2019-04-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
发行股份购买资产暨关联交易预案摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary of a major asset purchase and related party transaction plan by Zhejiang Huatong Pharmaceutical Co., Ltd. It includes extensive information about the transaction parties, the nature of the transaction, the expected impact on the company, payment methods, lock-up periods, and risk disclosures. The document references a '重大资产重组报告书' (major asset restructuring report) that will disclose audited financial data and valuation results once completed. The document is lengthy (15,000 characters) and contains substantive content about the transaction, its financial impact, and procedural steps. It is not merely an announcement of a report but a detailed transaction proposal and summary. This fits the category of a Capital/Financing Update (CAP), as it concerns a significant financing and capital structure change through issuance of shares to purchase assets and related party transactions. It is not an Annual Report, Audit Report, or Regulatory Filing, nor is it a simple announcement or proxy solicitation. Therefore, the appropriate classification is CAP with high confidence.
2019-04-19 Chinese
关于所提供信息真实性、准确性和完整性的承诺函
Regulatory Filings Classification · 95% confidence The document is a series of commitment letters regarding the truthfulness, accuracy, and completeness of information provided in relation to a transaction where Zhejiang Huatong Pharmaceutical Co., Ltd. plans to acquire 100% shares of Zhenong Group Co., Ltd. by issuing shares. The document contains multiple signatures from directors, supervisors, senior management, and controlling shareholders, affirming the authenticity of the information related to the transaction. There are no financial statements, audit opinions, or detailed financial data presented. The document is a legal commitment related to a transaction rather than a financial report or announcement of voting results. It does not fit into categories like Annual Report, Audit Report, Earnings Release, or M&A filings. It is a regulatory compliance document ensuring the accuracy of disclosed information for a capital transaction. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2019-04-19 Chinese
独立董事关于公司发行股份购买资产暨关联交易相关事项的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' pre-approval opinion regarding a company's issuance of shares to purchase assets and related party transactions. It discusses the transaction details, legal compliance, and benefits to the company and shareholders. It is not a full financial report, earnings release, or regulatory filing but a formal opinion related to a major asset acquisition and share issuance. The document length is short (1698 characters) and contains a formal opinion rather than financial data or results. This fits best under Capital/Financing Update (CAP) as it relates to issuance of shares and asset purchase transaction updates.
2019-04-19 Chinese
独立董事关于公司发行股份购买资产暨关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a proposed transaction involving the issuance of shares to purchase assets and related party transactions. It discusses the legal compliance, fairness, and benefits of the transaction, referencing relevant laws and regulations. The document does not contain financial statements or detailed financial data but rather an opinion on a specific corporate transaction. It is not an annual report, audit report, or financial supplement. It is also not a simple announcement or certification but a formal independent directors' opinion on a major asset restructuring transaction. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure related to a significant corporate transaction and independent directors' opinion, but not a full report or financial statement.
2019-04-19 Chinese
第三届监事会第十七次议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board (监事会) of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a major asset restructuring transaction involving the issuance of shares to purchase assets and related party transactions. It includes detailed descriptions of the transaction, legal compliance, pricing, payment methods, and related approvals. The document is not a full annual or interim financial report, nor is it a simple announcement of voting results or a proxy solicitation. It is a formal regulatory announcement related to a significant capital transaction and restructuring, consistent with a Capital/Financing Update (CAP) filing. The document length (6750 characters) and content support this classification rather than a brief announcement or a full financial report.
2019-04-19 Chinese
华金证券股份有限公司关于公司2018年度内部控制规则落实自查表的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the internal control self-assessment checklist of Zhejiang Huatong Pharmaceutical Co., Ltd. for the year 2018. It references regulatory requirements from the Shenzhen Stock Exchange and related laws, and confirms the accuracy and completeness of the company's internal control self-assessment. The document is short (983 characters) and primarily consists of an attestation or certification by the sponsoring institution rather than the internal control report itself. It does not contain financial statements or substantive financial data. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory compliance-related certification rather than a full audit report or annual report.
2019-04-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.